Allogeneic natural killer cells
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for Allogeneic natural killer cells, covering 2017-07-31 to 2025-11-06. Get the full timeline:
Most recent: Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]